Overview

Open Label Phase 1 Study in Japan for Patient With Advanced Solid Malignancies

Status:
Completed
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumour activity of ascending doses of AZD5363 under adaptable dosing schedules in Japanese patients with advanced solid malignancies.
Phase:
Phase 1
Details
Lead Sponsor:
AstraZeneca